BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37227179)

  • 1. Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
    de Godoy LL; Chawla S; Brem S; Mohan S
    Clin Cancer Res; 2023 Jul; 29(14):2588-2592. PubMed ID: 37227179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.
    Gonçalves FG; Chawla S; Mohan S
    J Magn Reson Imaging; 2020 Oct; 52(4):978-997. PubMed ID: 32190946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.
    Overcast WB; Davis KM; Ho CY; Hutchins GD; Green MA; Graner BD; Veronesi MC
    Curr Oncol Rep; 2021 Feb; 23(3):34. PubMed ID: 33599882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced magnetic resonance imaging in glioblastoma: a review.
    Shukla G; Alexander GS; Bakas S; Nikam R; Talekar K; Palmer JD; Shi W
    Chin Clin Oncol; 2017 Aug; 6(4):40. PubMed ID: 28841802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and opportunities for advanced neuroimaging of glioblastoma.
    Henssen D; Meijer F; Verburg FA; Smits M
    Br J Radiol; 2023 Jan; 96(1141):20211232. PubMed ID: 36062962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
    Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
    Vollmuth P; Foltyn M; Huang RY; Galldiks N; Petersen J; Isensee F; van den Bent MJ; Barkhof F; Park JE; Park YW; Ahn SS; Brugnara G; Meredig H; Jain R; Smits M; Pope WB; Maier-Hein K; Weller M; Wen PY; Wick W; Bendszus M
    Neuro Oncol; 2023 Mar; 25(3):533-543. PubMed ID: 35917833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
    Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
    Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
    Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.
    Verduin M; Compter I; Steijvers D; Postma AA; Eekers DBP; Anten MM; Ackermans L; Ter Laan M; Leijenaar RTH; van de Weijer T; Tjan-Heijnen VCG; Hoeben A; Vooijs M
    Dis Markers; 2018; 2018():2908609. PubMed ID: 29581794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
    Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
    BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.